MedTrace Logo

Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways

NCT05124288 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-05-13

No results posted yet for this study

Summary

This is a retrospective and prospective non-interventional multicenter observational study. Neither diagnostic approaches nor experimental drugs/procedure will be applied and the samples will take place at the same time as the samples will be taken during routinary clinical practice.

The aim of this study is to analyze the immunobiology of Acute Myeloid Leukemia (AML) relapses after allogeneic HSCT for the generation of guidelines and personalized therapeutic pathways.

Conditions

  • Acute Myeloid Leukemia, in Relapse

Interventions

OTHER

Observations on Relapsed AML Allogeneic Transplanted patients

This is not an interventional clinical study. This is a retrospective/prospective observational study on Relapsed AML Allogenic Transplanted patients. Additional samples will be collected during the standard practice.

Sponsors & Collaborators

  • Gruppo Italiano Trapianto di Midollo Osseo

    collaborator OTHER

  • Associazione Italiana per la Ricerca sul Cancro

    collaborator OTHER

  • Ciceri Fabio

    lead OTHER

Principal Investigators

  • Fabio Ciceri, MD · IRCCS Ospedale San Raffaele

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-18
Primary Completion
2026-12-20
Completion
2027-06-20

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05124288 on ClinicalTrials.gov